Home Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
 

Keywords :   


Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

2016-03-30 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Presentations Include Results from Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the companys broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: international development present programs

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
13.05Young face paying mortgage into retirement years
13.05Universal Credit claimants must seek 18 hours work
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
More »